Elicera Therapeutics develops cell and gene therapies for cancer treatment, with a focus on CAR T-cell therapies and oncolytic viruses.
Elicera Therapeutics has raised $5.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Elicera Therapeutics's investors include European Innovation Council, Vinnova.
Elicera Therapeutics is headquartered in Göteborg, Sweden.
Elicera Therapeutics develops cell and gene therapies for cancer treatment, with a focus on CAR T-cell therapies and oncolytic viruses.
Elicera Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elicera Therapeutics — Funding & Investors." VCBacked, May 29, 2026, https://www.vcbacked.co/company/elicera-therapeutics. Accessed September 29, 2026.
VCBacked. (2026). Elicera Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/elicera-therapeutics
{{cite web |title=Elicera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/elicera-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated